Company Filing History:
Years Active: 1992-1993
Title: Barry G. Shearer: Innovator in Protein Kinase Modulation
Introduction: Barry G. Shearer, an accomplished inventor based in Baltimore, MD, has made significant contributions to the field of pharmaceutical science. With a focus on protein kinase C (PKC) modulators, his work aims to address therapeutic needs surrounding inflammation and related conditions.
Latest Patents: Barry G. Shearer holds two patents that showcase his inventive spirit and dedication to scientific advancement. His latest patents include:
1. **Protein kinase C modulators**: This patent discloses PKC modulating compounds that inhibit PKC activity. It includes pharmaceutical compositions featuring these compounds, methods for using them to inhibit PKC activity in mammals, and intermediates useful in the preparation of the PKC modulating compounds.
2. **Method for treating inflammation**: This invention outlines a method for treating inflammatory conditions using specific compounds and compositions. The compounds are characterized by their specific molecular formula, where X can be methylene, ethylene, ethyleneoxy, or oxygen.
Career Highlights: Barry G. Shearer is affiliated with Nova Pharmaceutical Corporation, a company renowned for its commitment to innovation in pharmaceutical development. His work has been instrumental in enhancing the understanding of PKC's role in various medical conditions, leading to potential new treatments.
Collaborations: Throughout his career, Barry has collaborated with distinguished colleagues, including Ronald M. Burch and Raymond J. Patch. These partnerships reflect a shared commitment to advancing pharmaceutical science and improving patient care through innovation.
Conclusion: Barry G. Shearer exemplifies the characteristics of a dedicated inventor and researcher. His contributions to the field of protein kinase modulation hold promise for developing new therapies for inflammatory conditions, ensuring that his work will have a lasting impact on the world of medicine.